This site is intended for healthcare professionals

Reyvow showed significant therapeutic gains of 17-21% for pain freedom at 2 hours and met all 18 gated endpoints. Eli Lilly

Read time: 4 mins
Last updated:16th Mar 2021
Published:12th Sep 2020
Condition: Migraine/Headache
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest